April 2015 - Novocure

We have revised our Privacy Policy that is in effect as of May 25, 2018. Please click here to access it.

about us

corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.

leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.

corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.

ESG report Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
our therapy
our pipeline

clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.

novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media

press releases

press kits

media gallery

featured stories
investor relations

press releases

corporate presentation

events

annual reports

sec filings

stock information

corporate governance

faq

email alerts

NASDAQ: current stock price

186.66

4.65

last update 5/11/2021 16:00pm
careers

our locations

current job listings

New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015

April 10, 2015

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that four preclinical abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia to be held April 18-22, 2015. The four abstracts highlight the latest understanding of the mechanism of action of Tumor Treating Fields, or TTFields. …

Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors

April 09, 2015

April 09, 2015 07:35 PM Eastern Daylight Time MENLO PARK, Calif.–(BUSINESS WIRE)–Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Kieran T. Gallahue and W. Anthony Vernon to the company’s board of directors. Mr. Gallahue will serve …

about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
- ESG report Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
our therapy
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media
investor relations
careers
- our locations
- current job listings

Archive